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Summary
Cross-sectional imaging techniques are being increasingly used for disease
evaluation in patients with multiple myeloma. Whole body magnetic reso-
nance imaging (WB-MRI) scanning is superior to plain radiography in base-
line assessment of patients but changes following treatment have not been
systematically explored. We carried out paired WB-MRI scans in 21 newly
diagnosed patients prior to, and 8-weeks after, starting chemotherapy, and
analysed stringently selected focal lesions (FLs) for parametric changes. A
total of 323 FLs were evaluated, median 20 per patient. At 8 weeks, there
was a reduction in estimated tumour volume (eTV), and an increase in sig-
nal fat fraction (sFF) and apparent diffusion coefficient (ADC) in the group
as a whole (P < 0001). Patients who achieved complete/very good partial
response (CR/VGPR) to induction had a significantly greater increase in sFF
compared to those achieving ≤ partial response (PR; P = 0001). When anal-
ysed on a per-patient basis, all patients achieving CR/VGPR had a significant
sFF increase in their FL’s, in contrast to patients achieving ≤PR. sFF changes
in patients reaching maximal response within 100 days (fast responders)
were greater compared to slow responders (P = 0001). Receiver Operator
Characteristic analysis indicated that sFF changes at 8 weeks were the best
biomarker (area under the Curve 095) for an inferior response (≤PR). We
conclude that early lesional sFF changes may provide important information
on depth of response, and are worthy of further prospective study.
Keywords: magnetic resonance imaging, whole body, multiple myeloma,
bortezomib, treatment response.
The continued development of novel and highly effective
treatment protocols for multiple myeloma (MM) has pro-
duced a need for increasingly sophisticated tools to assess
response in this cancer. Biochemical measurements of para-
protein and heavy or light chains are global measures, while
bone marrow-based techniques have the disadvantage of ran-
dom sampling, and neither modality addresses the spatial
heterogeneity of this disease. Radiological techniques have
long been a part of disease assessments; plain radiographic
skeletal survey and magnetic resonance imaging (MRI) of the
spine have an established role in the diagnosis, staging and
assessment of insufficiency fracture risk of patients (Durie
et al, 2006; D’Sa et al, 2007; Hanrahan et al, 2010). The use
of cross-sectional imaging techniques [computed tomography
(CT), positron emission tomography (PET)-CT and MRI]
are confirmed to be more sensitive than plain radiography in
the detection of bone lesions (Zamagni et al, 2007; Bartel
et al, 2009; Regelink et al, 2013; Waheed et al, 2013). Impor-
tantly, the detection of more than one focal lesion (FL) on
cross-sectional imaging is now considered to fulfill the crite-
ria for symptomatic disease deserving of treatment (Rajku-
mar et al, 2014). Furthermore, advanced imaging techniques
have also been described to have clinical utility in prognosti-
cation. For instance, the number of FLs and metabolic
response on PET-CT following treatment were found to have
independent prognostic value in newly diagnosed patients
(Zamagni et al, 2011, 2015; Moreau et al, 2014).
There is growing evidence to support the use of whole
body MRI (WB-MRI) in the diagnostic work up of patients
with suspected or confirmed diagnosis of MM (Dutoit et al,
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2013; Dimopoulos et al, 2015). For example, WB diffusion
weighted (DW)-MRI is more sensitive than plain radiographs
in picking up FLs in patients with relapsed disease (Giles et al,
2015). MRI also provides valuable information on the degree
and pattern of marrow involvement, which may also carry
prognostic information. A diffuse pattern of marrow involve-
ment or high number of FLs on MRI is associated with inferior
outcomes in patients with symptomatic MM (Walker et al,
2007; Mai et al, 2015) whilst the detection of FLs in patients
with otherwise asymptomatic disease alters their risk profile
(Hillengass et al, 2010). Recently published guideline from the
National Institute for Health and Care Excellence (NICE) rec-
ommends WB-MRI for the investigation of patients with sus-
pected plasma cell disorders (NICE 2016).
Whilst initial disease evaluation in MM patients is
improved through the application of WB-MRI, current
response parameters remain based on global measures: serum
and urine M-protein levels, serum free light chain ratio and
bone marrow evaluation for clonal plasma cells, supple-
mented by minimal residual disease assessment by flow
cytometry or molecular techniques. Recently, functional MRI
techniques, such as contrast enhanced (CE) (Lin et al, 2010),
DW imaging (DWI) (Hillengass et al, 2011) and fat-water
imaging (Takasu et al, 2012), have become widely available
on clinical MRI scanners, providing an opportunity to
explore these techniques for response assessment. By detect-
ing intra- and extracellular water flux, DWI provides a mea-
sure of tissue cellularity and changes in apparent diffusion
coefficient (ADC) have been associated with treatment
response (Hillengass et al, 2011; Giles et al, 2014). CE imag-
ing is used to highlight abnormal vasculature, allowing detec-
tion of alterations of vasculature following therapy (Lin et al,
2010). Involvement by MM lesions leads to changes in
haematopoietic (red) and fatty (yellow) marrow, that can be
quantified by fat-water MRI techniques (Takasu et al, 2015).
In patients with symptomatic MM, signal fat fraction (sFF)
of lumbar spine was reported to be significantly lower when
compared to patients with asymptomatic disease (Takasu
et al, 2015). Response to treatment may therefore be
expected to lead to an increase in the sFF of involved bone,
but such changes have not been investigated as a response
measure. The aim of this study was to explore and compare
the use of DWI, CE and sFF functional MRI measures, in
the evaluation of newly diagnosed MM patients prior to, and
soon after starting chemotherapy.
Materials and methods
Patient cohort and study design
The study was conducted in accordance with the Declaration
of Helsinki and was approved by national research ethics
committee. Patients were included if they had a suspected
diagnosis of symptomatic multiple myeloma but were previ-
ously untreated, with chemotherapy or radiotherapy and
were able to undergo MRI scanning (i.e. no contraindication
to MRI). A prospective single-arm observational design was
used to study the patient cohort. Patients were recruited into
the study from multi-disciplinary team meetings and under-
went WB-MRI before starting treatment. A second WB-MRI
scan was performed after two cycles of induction chemother-
apy at a median of 8 weeks.
Laboratory Investigations and interphase FISH
Disease response was assessed after each cycle of chemother-
apy using serum and urine M-protein measurements, and
assigned according to International Myeloma Working Group
(IMWG) guidelines (Rajkumar et al, 2011). Baseline inter-
phase-fluorescence in situ hybridization (FISH) was performed
on CD138-selected plasma cells from bone marrow samples,
using probes for IGH translocations t(4;14), t(11;14) and t
(14;16), del(17p), del(13) and 1p-/1q+ (Smith et al, 2015).
WB-MRI technique
Imaging was performed using a single 30 T wide-bore MR
scanner (Ingenia; Phillips Healthcare, Best, the Netherlands).
Full body coverage (vertex to feet) was obtained through a
multi-station acquisition of contiguous body regions with the
manufacturers’ head coil, two anterior surface coils and
table-embedded posterior coils. Whole-body coronal pre-
contrast mDixon imaging was complimented by axial T2
weighted turbo spin echo (TSE), axial DWI (with 4 b-values:
b0, 100, 300, 1000) and finally, coronal CE mDIXON imag-
ing (following 20 ml of intravenous (IV) gadoterate meglu-
mine (Dotarem, Guebert, France). The average total scan
time was 67 min. Full scanning parameters are summarized
in Table I.
WB-MRI image analysis
The skeleton was divided into 10 anatomical locations (skull,
cervical spine, shoulder girdle, humorous, chest wall, thoracic
spine, lumbar spine, pelvis, femur and lower leg) and FLs at
pre- and post-treatment scans were localized by two radiolo-
gists (MHC and SP with more than 20 and 10 years experi-
ence in MR imaging, respectively) in consensus, without
knowledge of the results of all other imaging and non-ima-
ging investigations. The pattern of involvement was noted
for each patient as previously described using combination of
available sequences (Baur-Melnyk et al, 2005).
On DWI, FL’s were identified as focal areas of restricted
diffusion returning high signal intensity on DWI b1000
images compared to surrounding marrow, whilst on post-
contrast images, FL’s were identified as focal areas of
increased contrast uptake compared to surrounding marrow.
A 5-point Likert scale was used to score confidence of an
identified lesion representing myeloma (0 = non-diagnostic
quality images, 1 = unlikely, 2 = indeterminate, 3 = likely
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and 4 = highly likely disease). Likert scoring systems are
commonly employed in radiological research and clinical
practice (Rosenkrantz et al, 2013). Scoring was performed on
both DWI and post-contrast scans, and only matched lesions
on both images were selected for analysis as explained below.
To provide an objective per-patient global measure of dis-
ease, and for following treatment response, a maximum of
20 FLs per patient were selected for quantitative analysis
based on the following sequentially applied rules:
1. Lesions scored as 3 or 4 visible on matched DWI b1000
and post-contrast mDixon MRI were selected
2. Lesions < 5 mm in diameter were excluded (as their size
precludes accurate quantitation)
3. All lesions from locations containing 1 or 2 lesions
≥5 mm were included
4. The largest lesions from those remaining were selected to
make up the maximum of 20 FLs per patient
WB-MRI quantitative analysis
A region of interest (ROI) analysis for all selected lesions was
performed using Osirix (Version 40, Apple, Cupertino, CA,
USA). Quantitative biomarkers were estimated by single slice
analysis of FLs on slice depicting their largest dimension for
both scanning time-points as below:
Estimated tumour volume (eTV). Using the caliper tool, a
3-axis measurement of each selected FL was performed on
coronal post-contrast mDixon and axial b1000 DWI images.
Individual lesion volume was derived by (X*Y*Z/2).
Enhancement ratio (ER). Using the ROI tool, selected
lesions were carefully contoured on post-contrast water
only mDixon images and the average signal intensity (SI)
for each FL derived (SIpost-contrastW). The ROI was then
transferred to pre-contrast water only mDixon and average
SI derived (SIpre-contrastW). The signal intensities for indi-
vidual FL from the pre- and post-contrast water only
mDixon images were used to calculate ER as follows: 100*
(SIpost-contrastWSIpre-contrastW)/SIpre-contrastW.
Apparent diffusion coefficient (ADC). Using the ROI tool,
selected FLs were carefully contoured on the b1000 DW image
depicting their maximum diameter. The contours were copied
and pasted to the corresponding b0, b100 and b300 DW
images and average SI derived for each b-value. The ADC of
each selected FL was derived using a mono-exponential curve
fit of signal intensity verses b-value, within MATLAB 2011a
(MathWork, Natick, MA, USA) (Punwani et al, 2010).
Signal fat fraction (sFF). Using the ROI tool, contoured ROIs
on pre-contrast water only mDixon images (SIpre-contrastW)
were copied and pasted to the corresponding pre-contrast fat
only mDIXON images (SIpre-contrastF). sFF was calculated by
SIpre-contrastF/(SIpre-contrastF + SIpre-contrastW) (Messiou
et al, 2012).
Finally, as an internal control, sFF of normal appearing
femoral greater trochanter was assessed by a 3 cm3 circular
ROI at each time point.
Statistical analysis
Statistical analysis was performed using Prism software
(Prism Version 60, GraphPad Software, Inc., San Diego, CA,
USA). The normality of biomarkers distribution was assessed
by Kolmogorov–Smirnov test. Baseline eTV, ER, ADC and
sFF for each patient was correlated with age, sex, Interna-
tional Staging System (ISS), Beta-2 microglobulin, genetic
risk and response at end of induction therapy. Spearman’s
rank correlation coefficient (r) was calculated and signifi-
cance defined as P < 005. For temporal changes of MRI
parameters, a two-tailed Wilcoxon matched-pairs signed rank
test was used for paired samples that were not normally
distributed. For normally distributed data, a two-tailed
paired t-test was used for paired samples, and unpaired t-test
for independent samples.
Receiver operating characteristics (ROC) curves, for pre-
diction of patients achieving ≤ PR, were derived for percent-
age change in each MRI biomarker following treatment
[(8 weekbaseline) 9 100/baseline]. The area under the
curve (AUC) was quantified to assess performance for pre-
dicting patients achieving ≤ PR across all possible diagnostic
thresholds.
Table I. MRI sequence parameters.
Imaging plane
T2-TSE
mDixon
(pre- and
post-contrast*)
DWI
(b0, 100, 300,
1000)
Transverse Coronal Transverse
TE (ms) 80 102/18 71
TR (ms) 1228 30 6371
FOV (mm*mm) 500*300 502*300 500*306
Voxel size
(mm*mm)
1*1 21*21 4*42
Number of slices 40 120 40
Slice thickness (mm) 5 5 5
Acquisition matrix 500*286 144*238 124*72
ETL 91 2 39
Acceleration factor
(SENSE)
2 2 25
Pixel bandwidth
(Hz)
537 1992 3369
Scan time (s) 47 17 152
T2-TSE, T2-weighted turbo spin echo; mDixon, modified dixon;
DWI, diffusion weighted imaging; TE, time of echo; TR, time of rep-
etition; FOV, field of view; ETL, echo train length; SENSE, sensitivity
encoding.
*Contrast agent 20 ml intravenous gadoterate meglumine,
Dotarem, Guerbet, Villepint, France.
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Results
Patient treatment and disease response
Twenty-six patients were identified with symptomatic multi-
ple myeloma according to IMWG criteria (Durie et al, 2006).
One patient had no measurable FL on WB-MRI and was
excluded from further analysis. Demographic and disease
characteristics of the remaining 25 patients together with
details of induction regimens are shown in Table II. These
included PAD (Bortezomib, Doxorubicin, Dexamethasone;
17 patients), VTD (bortezomib, thalidomide, dexamethasone;
4 patients), CVD (cyclophosphamide, bortezomib, dexam-
ethasone; 3 patients) and MPV (melphalan, prednisone,
bortezomib; 1 patient). These regimens were administered as
either 3- or 4-week cycles. Patients received a total of 4–6
cycles of induction, with response assessment at the start of
each cycle and at the end of induction. Thirteen patients
achieved a complete response (CR) or very good partial
response (VGPR) to their first line of therapy, while the rest
achieved partial response (PR, n = 5), minimal response
(MR, n = 4) or stable disease/progressive disease (SD/PD,
n = 3).
Baseline WB-MRI evaluation and Lesion selection
Eight patients had a diffuse/focal pattern and 17 patients had
focal only pattern of involvement. On DWI, a median of 51
(range 1–139) FLs was identified for each patient, whilst 24
(range 2–128) FL’s were identified on post-contrast scans,.
For parametric analysis, a total of 394 FLs, that were
matched on DWI and post-contrast images [median of 20
FLs per patient (range 1–20)] were evaluated for the entire
cohort of 25 patients prior to chemotherapy. There was no
significant correlation between number of FLs, or any of the
baseline MRI parameters, with patient or disease features,
including sex, age, ISS stage, Beta-2 microglobulin and
genetic risk. There was a statistically significant negative cor-
relation between baseline sFF and depth of disease response
at the end of induction chemotherapy (Table S1). Patients
who achieved CR/VGPR had lower sFF in their FLs [median
025 arbitrary units (a.u.), interquartile range 021–038]
compared to those who achieved PR or less (035 a.u.,
interquartile range 029–049) (r = 059, P = 0002). There
was also a weak positive correlation (r = 040, P = 004)
between number of FLs on post-contrast MRI and depth of
the response achieved after induction (see Table S1).
Early mid-treatment scan
Out of twenty-five patients with measurable FLs on WB-
MRI, 22 patients attended for an early mid-treatment scan
after 2 cycles of treatment, at a median of 8 weeks from the
baseline scan. Of the three patients who did not attend for a
second scan, one could no longer tolerate the WB-MRI due
to bortezomib-related neuropathy; one underwent intra-
medullary nailing of femoral neck and could not be re-
imaged at the defined time point; and one withdrew from
the study. Of the remaining 22 patients, one patient received
interval radiotherapy and was excluded from the analysis.
Temporal changes of WB-MRI parameters were assessed in
the remaining 21 patients.
Changes in quantitative WB-MRI parameters at 8 weeks
A total of 323 FLs were evaluable for pre- and post-treatment
analysis. Figure 1 shows a pelvic FL at baseline and after
8 weeks of treatment, illustrating change in lesional size and
appearance. Summarizing changes across the entire cohort of
21 patients, eTV decreased significantly (from median
023 cm3 at baseline to 012 cm3 at 8 weeks, P < 0001),
while there was no significant change in ER (median baseline
and 8 weeks ER, 1043% and 1282%, respectively, P = 078).
Significant increases in both ADC and sFF were seen across
the entire cohort; ADC increased from 075 9 103 mm2/s
Table II. Patient demographics, disease parameters and treatment.
Patient characteristic (N = 25)
Number or median
(range)
Age, years 55 (36–72)
Sex, male/female: 15/10
Chain isotype
IgG 16
IgA 5
Light chain 4
ISS stage
I 10
II 11
III 4
DS-PLUS stage
I 1
II 3
III 21
Induction regimen
PAD 17
CVD 3
VTD 4
MPV 1
Bone marrow percentage plasma cells 65 (13–90)
Beta-2 microglobulin (mg/l) 35 (13–113)
Albumin (g/l) 40 (30–53)
Creatinine 79 (56–105)
Genetic risk group
Standard risk 16
High risk 9
ISS, international staging system; DS-PLUS, durie-salmon PLUS stag-
ing; PAD, bortezomib, doxorubicin, dexamethasone; CVD,
cyclophosphamide, bortezomib, dexamethasone; VTD, bortezomib,
thalidomide, dexamethasone; MPV, melphalan, prednisone,
bortezomib.
A. Latifoltojar et al
4 ª 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
to 134 9 103 mm2/s (P < 0001) and sFF increased from
027 a.u. to 047 a.u. (P < 0001) at 8 weeks (Fig 2).
Correlation of WB-MRI parameters with IMWG disease
response
Of the 21 patients with baseline and 8-week scans available
for analysis, 12 patients achieved CR/VGPR to their first line
regimen, while disease responses in the remaining 9 were
PR (n = 3), MR (n = 4), SD (n = 1) and PD (n = 1). One
patient who had biochemically-defined PR had residual
heavy disease burden in the bone marrow (90%) and was re-
classified as MR. Details of these patients are given in
Table S2. A total of 208 (median 20 range 4–20) FLs in the
CR/VGPR group and 115 (median11 range 1–20) FLs in the
≤PR group were evaluated. The changes in each parameter
for these two groups of patients are summarized in Table III,
and Figure S1. Significant changes in eTV, sFF and ADC
(P < 0001 for all) were noted for both groups, but no signif-
icant change was observed in ER for either group.
We then compared the magnitude of change in eTV, sFF
between the CR/VGPR and the ≤PR patient groups. While
there was a significant reduction in eTV in both groups fol-
lowing treatment, the magnitude of change was similar
(P = 062). On the other hand, the magnitude of change in
sFF was significantly greater in the CR/VGPR (+021  006,
mean  SD) compared with the ≤PR group (+006  008,
P = 0001). Although the changes in ADC were greater in
the CR/VGPR group (+047  039) compared with the ≤PR
group (+018  018), this did not reach significance
(P = 0053) (Fig 3).
As internal controls for each patient, we also evaluated
sFF of uninvolved greater trochanteric ROI. Two patients
from the ≤PR group were excluded from this analysis due to
diffuse involvement of greater trochanter and artefact on MR
images. There was no significant change in greater trochan-
teric sFF in the CR/VGPR group (n = 12), and the ≤PR
group (n = 7) (Figure S2).
Consistency and speed of lesional responses
Data for the sFF of each lesion in representative patients
achieving VGPR, PR and SD are shown in Fig 4, where it
can be seen that, while all lesions manifest an increase in sFF
in the patient with VGPR, responses are more mixed and
individual lesional changes more variable in patients who did
not achieve a deep biochemical response. Analysing sFF
changes in each patient, every patient achieving CR/VGPR
had a significant increase in lesional sFF, except for one
patient who had only 4 FL’s for analysis. One patient with a
single FL who achieved PR was excluded from per patient
analysis. In contrast to the CR/VGPR group, none of the 6
patients with <PR had a significant change in the sFF of their
FLs, whilst two out of the three patients with PR
demonstrated a significant increase in sFF. Eight out of the
12 patients achieving CR/VGPR had a significant rise in
ADC of their FL’s, while 2 out of 6 patients with <PR had a
significant rise in ADC of their FL’s (Table S3).
We also investigated if WB-MRI changes at 8 weeks corre-
lated with speed of response. Patients were divided into two
subgroups based on the time to maximum response (≤ or
>100 days). Patients who reached maximum response
≤100 days (n = 11) had significantly greater changes in sFF
(8 weeks-baseline) when compared to those with whose time
to maximum response was >100 days (n = 10, P < 0001).
No significant difference in ADC changes was observed
between these two groups of patients (Fig 5).
Predictive value of sFF and ADC changes
Finally, we carried out ROC analysis to evaluate the predic-
tive value of percentage changes of MRI biomarkers for
response quality (CR/VGPR versus ≤ PR). Area under the
curve analysis showed an AUC of 095 (95% confidence
interval 087–100) for percentage changes of sFF as predictor
of ≤ PR whist other MRI biomarkers were less reliable for
predicting ≤PR (Figure S3 and Table S4).
Discussion
In this study, we investigated the possible utility of paramet-
ric analysis of WB-MRI scanning in newly diagnosed MM
patients for the assessment of baseline characteristics, as well
as for early assessment of treatment response. We observed
that patients who achieved major responses (CR/VGPR) had
a lower sFF in their FLs compared to patients who achieved
≤ PR. We also observed a significant decrease in eTV at
8 weeks that appeared to be independent of response depth.
On the other hand, changes in lesional sFF were significantly
greater in patients achieving CR/VGPR, when compared with
those whose disease response was PR or less. A trend to simi-
lar differences in ADC changes was also observed. The mag-
nitude of change in lesional sFF also seemed to differentiate
between fast and slow responders. ROC analysis indicated
the superior value of sFF changes at 8 weeks in predicting a
major response.
Treatment-related increases in ADC have previously been
reported in MM patients (Messiou et al, 2012; Bonaffini
et al, 2015). Messiou et al (2012) assessed ADC of up to five
ROIs on ADC maps (including diffuse marrow involvement
and normal appearing bone marrow, as opposed to FL only),
and observed an initial increase of ADC at 4–6 weeks of
treatment in responding patients, followed by a decrease at
20 weeks. These authors also reported that significantly lower
percentage of pixels representing fatty marrow in baseline
ADC histograms in patients with active myeloma (n = 8,
272%) compared to patients in remission (n = 12, 830%).
By implementing a two b value (b50, 900 s/mm2) WB-DWI
Whole Body MRI for Response Monitoring in Multiple Myeloma
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on 15 T scanner and segmenting all area of visible marrow,
Giles et al (2014) showed that the ADC increased in 95%
(19/20) of responding patients, but that it decreased in all
non-responders (5/5). Given that myeloma is a patchy dis-
ease, we selected stringently defined areas of involved skele-
ton, hence the emphasis on FLs. Horger et al (2011)
(A1) (A2)
(B1) (B2)
(C1) (C2)
(D1) (D2)
Fig 1. Representative images of a focal lesion
(FL) in left pelvis showing changes after
8 weeks. A FL (red arrow) on (A) pre-contrast
fat-only, (B) pre-contrast water-only, (C) post-
contrast water only mDixon and (D) b1000
diffusion weighted imaging at baseline
(A1–D1) and 8 weeks (A2–D2) in a patient
who achieved very good partial response
(VGPR) after induction chemotherapy. Esti-
mated tumour volume (eTV), signal fat frac-
tion (sFF), enhancement ratio (ER) and
apparent diffusion coefficient (ADC) were
45 cm3, 011 a.u., 1678% and
113 9 103 mm2/s at baseline, respectively. At
8 weeks after starting chemotherapy, eTV, sFF,
ER and ADC were 396 cm3, 023 a.u., 1975%
and 197 9 103 mm2/s, representing a 12%
reduction in eTV, 109% increase in sFF, 176%
increase in ER and 743% increase in ADC.
A. Latifoltojar et al
6 ª 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
analysed both intra and extramedullary FLs >20 mm and
demonstrated a 639% increase (range 87–2112%) in their
responding cohort compared to 78% reduction in ADC in
their only non-responding patient. In line with a previous
report, we did not observe any significant change in the
enhancement of FLs following treatment (Lin et al, 2010). It
is possible that changes in angiogenesis within FL are not
optimally captured at this early time point of treatment. Per-
sistent increased angiogenesis has been previously reported in
MM patients following successful treatment (Rajkumar et al,
1999).
Previous reports investigating sFF quantification in bone
marrow are scarce. Using iterative decomposition of water
and fat with echo asymmetric and least-squares estimation
(IDEAL) Dixon-based MRI, Takasu et al (2015) demon-
strated a significant decrease in sFF in the lumbar spine in
symptomatic myeloma patients, when compared with asymp-
tomatic multiple myeloma. We have chosen to concentrate
our analysis on FL because the presence of FL is recognized
to be more relevant (compared to diffuse marrow signal
abnormality) to disease pathogenesis and risk assignment
(Rajkumar et al, 2014), hence signal changes in these dis-
eased areas are likely to be more prognostically relevant. To
the best of our knowledge, our work is the first to systemati-
cally examine changes in the sFF of FLs following initiation
of treatment in newly diagnosed MM patients, to report
Fig 2. Temporal changes in MRI parameters
across entire cohort. Signal fat fraction (sFF),
apparent diffusion coefficient (ADC), estimated
tumour volume (eTV) and enhancement ratio
(ER) at 8 weeks compared with baseline across
the entire cohort (n = 21). Data for each
patient (median for each parameter) are given.
Wilcoxon signed-matched rank test was used
to assess temporal changes of MRI parameters
and P < 005 defined as significant.
Table III. Baseline and 8 week imaging parameters (median and interquartile range, IQR) for CR/VGPR and ≤PR patients. Temporal changes in
each group were assessed using Wilcoxon matched-pairs signed rank test and significance defined as P < 005.
Scan Median eTV (IQR) Median ER (IQR) Median ADC (IQR) Median sFF (IQR)
CR/VGPR
(n = 12)
Baseline 024 (015–086) 1147 (972–1902) 079 (066–126) 024 (020–027)
8 weeks 013 (010–047)* 1406 (884–1842) 150 (088–183)* 044 (037–063)*
≤ PR
(n = 9)
Baseline 017 (008–087) 848 (736–1219) 066 (052–087) 040 (029–054)
8 weeks 008 (004–059)* 1278 (560–1945) 075 (051–127)* 048 (032–060)*
CR, complete response; VGPR, very good partial response; PR, partial response; eTV, estimated total tumour volume; ER, enhancement ratio;
ADC, mean apparent diffusion coefficient; sFF, signal fat fraction; IQR, interquartile range.
*Significant change (P < 005) compared with baseline scan.
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significant increases in sFF after 8 weeks of treatment and
the potential utility of early sFF changes as a predictor of
depth of response to induction chemotherapy.
Depth of response in newly diagnosed patients undergoing
novel agent-containing regimens has been shown to correlate
with disease-free and, in some cases, overall survival
(Martinez-Lopez et al, 2011; Vij et al, 2015). Longer follow-up
of our patient cohort is needed in order to explore an associa-
tion of MRI response parameters with survival, as has been
reported for PET-CT negativity (Zamagni et al, 2011, 2015).
Our results also need confirmation in a larger cohort of
patients treated prospectively, ideally in a uniform manner.
Fig 3. Comparison of changes in MRI parame-
ters between response groups. Changes in sig-
nal fat fraction (sFF), apparent diffusion
coefficient (ADC), estimated tumour volume
(eTV) and enhancement ratio (ER) were com-
pared between the CR/VGPR and ≤PR patient
groups. Box and whisker plot of changes in
each parameter [(8 weeks)(baseline)] for each
group. The boundaries of the box show 25th
and 75th percentiles, and the line within the
box is the median. Whiskers show 10th and
90th percentiles. Means are shown (+).An
unpaired t-test was used to compare changes
between the two patient groups and P < 005
was defined as significant. CR, complete
response; VGPR, very good partial response;
PR, partial response.
Fig 4. Lesional signal fat fraction (sFF) changes for representative patients achieving very good partial response (VGPR), partial response (PR)
and stable disease (SD) following induction chemotherapy. Data points in each graph represent focal lesions at baseline and 8 weeks after starting
treatment. To assess the temporal changes, a Wilcoxon matched-pairs signed rank test was used and P < 005 was defined as significant.
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We chose major response (CR/VGPR) category for correlative
analysis, because in this era of novel regimens where the
majority of patients are likely to achieve at least a PR, the
attainment of a deep response is not only achievable in a sig-
nificant number of patients, but serves as better indicator of
long term benefit (Lional & Andeson, 2014). If the superior
predictive value of sFF is confirmed in a larger study, the use
of WB-MRI to assess sFF changes early during treatment will
aid real time response assessment. By providing an early indi-
cator of response quality, such analyses can be incorporated
into risk-stratified protocols. Such radiological parameters
need integration with current platforms for risk assignment
that are a composite of baseline features and response depth/
quality.
A major attraction of WB-MRI quantitative parameters is
the applicability to patients with non-secretory or oligo-secre-
tory disease, who have traditionally not been studied in clini-
cal trials and for whom accurate disease response assessment
can be challenging. For such patients, WB-MRI represents a
non-invasive alternative to repeated bone marrow sampling,
with the added advantage of providing more comprehensive
information about non-axial and extra-medullary disease. We
noted that some patients showed lesional variation in the sFF
and ADC changes at 8 weeks (see representative patients with
PR and SD in Fig 4). While targeted biopsy of individual
lesions is required to confirm active disease, the ability to
track individual lesions within a patient may provide prognos-
tic information. Evidence is accumulating that MM is a multi-
clonal disease from diagnosis (Bolli et al, 2014; Lohr et al,
2014; Walker et al, 2014), and spatial heterogeneity in radio-
logical response to therapy may reflect sub-clonal differences
in treatment response. The ability to track individual FLs for
longitudinal monitoring may be especially valuable in patients
harbouring adverse genetic lesions. For such patients, further
follow-up scans to monitor “resistant” lesions may be neces-
sary to pre-empt rapid disease reactivation.
This study was performed on a single MRI scanner, how-
ever, as the MRI pulse sequence used to perform these mea-
surements is routinely available on all scanners, and the
quantification steps involved are simple, there should be few
barriers to generalization. Despite promising results concern-
ing the application of ADC as MRI biomarker for monitor-
ing response in various soft tissue and skeletal tumours
(Punwani et al, 2010; Giles et al, 2014), generalization of
ADC remains challenging (Koh et al, 2011). ADC quantita-
tion could be affected by several factors, such as number and
choices of b values, mathematical model for data fitting, soft-
ware for data analysis and choices of applied sequence
parameters (Koh et al, 2011; Celik, 2016). Furthermore, in
the bone marrow microenvironment, the temporal changes
of ADC following myelomatous infiltration and treatment
are complex and affected by several factors, such as cell size,
bulk flow in capillaries, cellular architecture and the amount
of fatty (yellow) marrow (Messiou & Kaiser, 2015). At the
very least, lesional sFF will provide complementary informa-
tion to ADC, but may well prove superior in reproducibility
and practical application. For example, a 10-min protocol
could be performed for sFF quantification of FL to provide a
response marker of treatment.
In conclusion, we have demonstrated that the assessment
of newly diagnosed patients using WB-MRI to derive sFF
and ADC of stringently selected FLs has potential utility in
disease response assessment that will complement currently
available techniques. sFF changes appear to be most predic-
tive of deep and rapid responses in newly diagnosed patients
undergoing induction therapy. Provided these imaging
biomarkers are prospectively validated in larger cohorts, they
may prove a valuable addition to the current risk platforms
Fig 5. Magnitude of changes in signal fat fraction (sFF) and apparent diffusion coefficient (ADC) according to speed of biochemical response.
Changes from baseline [(8 weeks)(baseline)] were assessed separately for patients who reached their maximal response (lowest paraprotein level)
within 100 days (n = 11) versus those who took longer than 100 days (n = 10). Box and whisker plots of changes in sFF and ADC. The bound-
aries of the box show 25th and 75th percentiles, and the line within the box is the median. Whiskers show 10th and 90th percentiles. Means are
shown (+). An unpaired t-test was used to assess changes in MRI parameters [(8-week values)(baseline values)] between the two patient groups
and P < 005 was defined as significant.
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in MM patients, integrating baseline features and treatment
response.
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